Division of Teva Pharmaceutical Industries Ltd.
Latest From Anda Inc.
Debt-fueled acquisitions helped Teva, Shire and Allergan report well-received fourth-quarter earnings. But sector circumstances have changed since 2016 and the ability to grow by debt-funded acquisition is now severely restricted.
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
Pfizer signed multiple billion-dollar deals, including buying AstraZeneca's anti-infectives portfolio for $1.6 billion and acquiring Medivation – and the blockbuster cancer drug Xtandi – for $14 billion. Follow-on public offerings accounted for 52% of both biopharma and device financing.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2016.
- Generic Drugs
- Therapeutic Areas
- Valmed Pharmaceutical
- North America
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
- Albert Paonessa, EVP & COO
- Contact Info
Phone: (800) 331-2632
2915 Weston Rd.
Weston, FL 33331
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.